2742 related articles for article (PubMed ID: 19601711)
1. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
[TBL] [Abstract][Full Text] [Related]
2. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
[TBL] [Abstract][Full Text] [Related]
3. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
4. Economic cost of community-acquired pneumonia in New Zealand adults.
Scott G; Scott H; Turley M; Baker M
N Z Med J; 2004 Jun; 117(1196):U933. PubMed ID: 15280937
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia.
Eber MR; Laxminarayan R; Perencevich EN; Malani A
Arch Intern Med; 2010 Feb; 170(4):347-53. PubMed ID: 20177037
[TBL] [Abstract][Full Text] [Related]
6. Direct medical costs of bronchiolitis hospitalizations in the United States.
Pelletier AJ; Mansbach JM; Camargo CA
Pediatrics; 2006 Dec; 118(6):2418-23. PubMed ID: 17142527
[TBL] [Abstract][Full Text] [Related]
7. Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP).
Kozma CM; Dickson M; Raut MK; Mody S; Fisher AC; Schein JR; Mackowiak JI
J Med Econ; 2010; 13(4):719-27. PubMed ID: 21091099
[TBL] [Abstract][Full Text] [Related]
8. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
9. National estimates of the inpatient burden of pediatric bipolar disorder in the United States.
Berry EA; Heaton PT; Kelton CM
J Ment Health Policy Econ; 2011 Sep; 14(3):115-23. PubMed ID: 22116169
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population.
Yu H; Rubin J; Dunning S; Li S; Sato R
J Am Geriatr Soc; 2012 Nov; 60(11):2137-43. PubMed ID: 23110409
[TBL] [Abstract][Full Text] [Related]
11. Community acquired pneumonia and direct hospital cost.
Doruk S; Tertemiz KC; Kömüs N; Uçan ES; Kilinç O; Sevinç C
Tuberk Toraks; 2009; 57(1):48-55. PubMed ID: 19533437
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical industry research and cost savings in community-acquired pneumonia.
Kessler LA; Waterer GW; Barca R; Wunderink RG
Am J Manag Care; 2002 Sep; 8(9):798-800. PubMed ID: 12234020
[TBL] [Abstract][Full Text] [Related]
14. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups.
Tong KB; Lau CJ; Murtagh K; Layton AJ; Seifeldin R
Int J Infect Dis; 2009 Jan; 13(1):24-36. PubMed ID: 18621562
[TBL] [Abstract][Full Text] [Related]
15. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX; Liu GG; Christensen DB; Fu AZ
Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
Dasta JF; Chiong JR; Christian R; Lin J
Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
[TBL] [Abstract][Full Text] [Related]
17. Supplemental calcium for the prevention of hip fracture: potential health-economic benefits.
Bendich A; Leader S; Muhuri P
Clin Ther; 1999 Jun; 21(6):1058-72. PubMed ID: 10440627
[TBL] [Abstract][Full Text] [Related]
18. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
Smith DG; Cerulli A; Frech FH
Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with hospital length of stay and hospital charges of motor vehicle crash related hospitalizations among children in the United States.
Gardner R; Smith GA; Chany AM; Fernandez SA; McKenzie LB
Arch Pediatr Adolesc Med; 2007 Sep; 161(9):889-95. PubMed ID: 17768290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
